Trial Profile
Retrospective study analyzing the efficacy and toxicity of P-Gemox (Pegaspargase, Gemcitabine, Oxaliplatin) in the treatment of Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma (ENKTL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Pegaspargase (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology